Introduction
Methods
Category, grade | Definition |
---|---|
Strength of recommendation | |
A | Good evidence to support a recommendation for use |
B | Moderate evidence to support a recommendation for use |
C1 | Recommendation for use regardless of poor evidence |
C2 | Poor evidence to support a recommendation for use |
D | Good-to-moderate evidence to support a recommendation against use |
Quality of evidence | |
I | Evidence from ≥1 properly randomized, controlled trial |
II | Evidence from ≥1 well-designed clinical trial, without randomization from cohort or case-controlled analytical studies, multiple time-series, or dramatic results from uncontrolled experiments. |
III | Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees |
Indications for TDM
Executive summary
Literature review
Pharmacokinetics–pharmacodynamics (PK–PD)
Executive summary
Literature review
Methods of TDM
Executive summary
Literature review
Target serum concentrations in TDM
Executive summary
Literature review
Initial administration regimen
Executive summary
Loading dose (on day 1) | Maintenance dose | |
---|---|---|
IV administration | 6 mg/kg twice daily | 3–4 mg/kg twice daily |
Oral administration (between meals) | ||
≥40 kg | 300 mg twice daily | 150–200 mg twice daily |
<40 kg | 150 mg twice daily | 100 mg twice dailya
|
Literature review
TDM in patients under particular clinical conditions and pediatric considerations
Executive summary
Literature review
Drug–drug interactions (Table 3)
Executive summary
Drug | CYP | Mechanism | ||
---|---|---|---|---|
2C9 | 2C19 | 3A4 | ||
Contraindications | ||||
Rifampin | ○ | Because of induction of the CYP3A4 metabolism by rifampin, rifampin decreased the steady-state C
max and AUC of VRCZ | ||
Rifabutin | ○ | Because of induction of the CYP3A4 metabolism by rifabutin, rifabutin decreased the steady-state C
max and AUC of VRCZ | ||
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of rifabutin | ||||
Efavirenz | ○ | ○ | ○ | Because of induction of the CYP2C19 and 2C9 metabolism by efavirenz, efavirenz decreased the steady-state C
max and AUC of VRCZ |
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of efavirenz | ||||
Ritonavir | ○ | ○ | Because of induction of the CYP2C19 and 2C9 metabolism by ritonavir, ritonavir decreased the steady-state C
max and AUC of VRCZ | |
Carbamazepine | ○ | Because of induction of the CYP3A4 metabolism by carbamazepine, carbamazepine decreased the steady-state C
max and AUC of VRCZ | ||
Barbital | ○ | Because of induction of the CYP3A4 metabolism by barbital, barbital decreased the steady-state C
max and AUC of VRCZ | ||
Phenobarbital | ○ | Because of induction of the CYP3A4 metabolism by phenobarbital, phenobarbital decreased the steady-state C
max and AUC of VRCZ | ||
Pimozide | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration and risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) of pimozide | ||
Quinidine | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration and risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) of quinidine | ||
Ergotamine | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration of ergot derivative and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) of ergotamine | ||
Triazolam | ○ | Because of inhibition of the CYP3A4 triazolam metabolism by VRCZ, VRCZ increased plasma concentrations and potential of triazolam | ||
Cautions | ||||
Phenytoin | ○ | ○ | Because of induction of the CYP3A4 metabolism by phenytoin, phenytoin decreased the steady-state C
max and AUC of VRCZ | |
Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of phenytoin | ||||
Inhibitor of HIV protease (excluded indinavir): saquinavir, amprenavir, nelfinavir | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration of HIV protease inhibitor | ||
Because of inhibition of the CYP3A4 metabolism by HIV protease inhibitor, HIV protease inhibitor increased plasma concentration of VRCZ | ||||
(n*) nucleoside reverse transcriptase inhibitor (NNRTI): Delavirdine | ○ | Because of inhibition of the CYP3A4 metabolism by NNRTI, NNRTI increased plasma concentration of VRCZ | ||
Because of induction of the CYP3A4 metabolism by NNRT, NNRT decreased plasma concentration of VRCZ | ||||
Because of inhibition of the CYP3A4 metabolism by VRCZ VRCZ increased plasma concentration of NNRTI | ||||
Cyclosporine | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of cyclosporine | ||
Tacrolimus | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of tacrolimus | ||
Warfarin | ○ | Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ increased the prothrombin time of warfarin | ||
Omeprazole | ○ | ○ | Because of inhibition of the CYP2C19 and 3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of omeprazole | |
Midazolam | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration of midazolam | ||
HMG-CoA reductase inhibitor | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration of HMG-CoA reductase inhibitor | ||
Diazepam | ○ | ○ | Because of inhibition of the CYP2C9 and 3A4 metabolism by VRCZ, VRCZ increased the steady-state AUC and elimination half-life of diazepam | |
Zolpidem | ○ | ○ | Because of inhibition of the CYP2C9 and 3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of zolpidem | |
Sulfonylureas; tolbutamide | ○ | Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ increased plasma concentration of sulfonylureas | ||
Vinca alkaloids anticancer agents | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased plasma concentration of vinca alkaloids | ||
Vincristine | ||||
Vinblastine | ||||
Oxycodone | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of oxycodone | ||
Fentanyl | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state AUC of fentanyl | ||
Ibuprofen | ○ | Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ increased steady-state C
max and AUC of ibuprofen | ||
Diclofenac | ○ | Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ increased steady-state C
max and AUC of diclofenac | ||
Oral contraceptive; norethindrone and ethinyl estradiol | ○ | ○ | Because of inhibition of the CYP2C19 metabolism by norethindrone and ethinyl estradiol, norethindrone and ethinyl estradiol increased steady-state C
max and AUC of VRCZ | |
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased steady-state C
max and AUC of norethindrone and ethinyl estradiol | ||||
St. John’s wort | ○ | ○ | Because of induction of the CYP3A4 and 2C19 metabolism by St. John’s wort, St. John’s wort decreased the steady-state AUC of VRCZ | |
Overseas reference | ||||
Sirolimus | ○ | Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ increased the steady-state C
max and AUC of sirolimus | ||
Digoxin, cimetidine, ranitidine | No change |